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Abstract
Purpose—Evidence suggests substantial disparities in breast cancer survival by socioeconomic 
status (SES). We examine the extent to which receipt of newer, less invasive, or more effective 
treatments – a plausible source of disparities in survival – varies by SES among elderly women 
with early stage breast cancer.
Methods—Multivariate regression analyses applied to 11,368 women (age 66–90 years) 
identified from SEER-Medicare as having invasive breast cancer diagnosed in 2006–2009. 
Socioeconomic status was defined based on Medicaid enrollment and level of poverty of the 
census tract of residence. All analyses controlled for demographic, clinical health status, spatial 
and healthcare system characteristics.
Results—Poor and near-poor women were less likely than high SES women to receive sentinel 
lymph node biopsy and radiation after breast conserving surgery (BCS). Poor women were also 
less likely than near-poor or high SES women to receive any axillary surgery and adjuvant 
chemotherapy. There were no significant differences in use of aromatase inhibitors (AI) between 
poor and high SES women. However, near-poor women who initiated hormonal therapy were 
more likely to rely exclusively on tamoxifen, and less likely to use the more expensive but more 
effective AI when compared to both poor and high SES women.
Conclusions—Our results indicate that SES disparities in the receipt of treatments for incident 
breast cancer are both pervasive and substantial. These disparities remained despite women’s 
geographic area of residence and extent of disease, suggesting important gaps in access to effective 
breast cancer care.
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INTRODUCTION
Traditionally, population incidence and mortality rates of women with incident breast cancer 
were both lower among patients of lower socioeconomic status (SES). During the past three 
decades, however, this situation has changed: while the incidence of breast cancer remained 
lower among this group, mortality is now significantly higher among women of low SES 
relative to their high SES counterparts [1]. While the literature is replete of studies 
documenting disparities in breast cancer mortality by socioeconomic status [1–11], and 
notwithstanding the fact that eliminating such disparities is a national priority of 
HealthyPeople 2020, relatively little is known about its underlying source.
One plausible source of the observed disparities in breast cancer outcomes may be 
differential receipt of newer or more effective treatments by women of lower socioeconomic 
status. To the extent that, all else constant, there is variation in treatment attributed solely to 
a patient’s socioeconomic status, the SES disparity in outcomes is likely to follow. Multiple 
studies have shown disparity in receipt of breast-conserving surgery (BCS) by SES [6,12–
16]. Relatively little is known, however, about disparities in other initial surgical (e.g. 
axillary surgery) or adjuvant therapies (e.g. chemotherapy, radiation, hormonal therapy). 
Few national studies have assessed breast cancer treatment disparities by socioeconomic 
status (SES), particularly within lower SES groups, in the United States.
The purpose of this study is to identify socioeconomic disparities in receipt of newer, less 
invasive, or more effective breast cancer treatments. We hypothesized that poor and near-
poor women with incident breast cancer are less likely than women of higher socioeconomic 
status to receive such recommended initial treatments and adjuvant therapies.
Methods
Study Population and Data Sources
The main data source for the study was the Surveillance, Epidemiology and End Results 
(SEER)-Medicare database, a linkage of two large population-based datasets that provide 
detailed information about elderly persons with cancer. Detailed clinical information, 
including extent of disease at presentation and cause of death, were available from the SEER 
program. Information on subject’s cancer treatment as well as on demographic and 
socioeconomic characteristics were obtained from linked Medicare enrollment and claims 
files. These data were further supplemented by geocoded Census data [17].
The study sample consisted of elderly women between the ages of 66 and 90 years old 
identified from the SEER-Medicare database as having unilateral, invasive, stage I–III breast 
cancer diagnosed from July 2006 through December 2009. The sample was further restricted 
to those continuously enrolled in traditional (Fee-for-Service, FFS) Medicare for at least 12 
months prior to their incident breast cancer diagnosis date in order to enable us to measure 
comorbidities.
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Outcome Measures
The main outcome of this study was receipt of specific breast cancer treatments. 
Specifically, we evaluated whether an axillary surgery was performed and type of axillary 
surgery performed (sentinel lymph node dissection only (SLNB), axillary lymph node 
dissection only (ALND), both SLNB and ALND); receipt of radiation therapy, receipt of 
chemotherapy (neoadjuvant and adjuvant), and receipt of newer, more effective adjuvant 
endocrine therapy, based on the 2005 American Society of Clinical Oncology (ASCO) 
recommendations prevailing during the study period, which indicated that adjuvant 
treatment for postmenopausal women with hormone-receptor positive breast cancer should 
include an aromatase inhibitor [18]. Identification of 2005 ASCO guideline-discordant 
endocrine therapy regimen was based on patients’ exclusive use of tamoxifen during the first 
four consecutive years following first endocrine therapy claim. Patients with at least one 
claim for any aromatase inhibitor (AI) during the 4-year period were considered guideline-
compliant and served as the reference group for the analysis.
Socioeconomic Status
Using individual-level enrollment information and geographic identifiers provided under a 
restricted Data Use Agreement with each of the 16 SEER registries, we constructed four 
mutually exclusive indicators of beneficiaries’ socioeconomic status – poor, near poor, 
middle and high SES – as follows. First, we classified all Census tracts in states with a 
SEER registry into composite poverty quartiles based on per capita income (PCI), 
proportion of families below poverty line (POVT) and median household income (HHI) of 
tracts within each state. A study subject was then classified as “poor” if she was enrolled in 
her state of residence’s Medicaid or a state buy-in program, regardless of Census tract of 
residence; “near-poor” if she was not enrolled in Medicaid or a state buy-in program but 
lived in a Census tract ranking in the highest quartile of poverty (defined as lowest quartile 
of both PCI and HHI and upper quartile of POVT); “high SES” if she was not enrolled in 
Medicaid or a state buy-in program and lived in a Census tract ranking in the lowest quartile 
of poverty (defined as upper quartile of both PCI and HHI and lowest quartile of POVT). 
Given its heterogeneity, we excluded from our analyses subjects belonging to the residual 
“middle income” group of women who were neither enrolled in a public subsidy program 
nor resided in a Census tract ranking in the lowest or highest quartile of poverty.
Other covariates
Women were classified according to their race/ethnicity as White non-Hispanic, Black/
African American non-Hispanic, Hispanic, Asian or other race/ethnicity. Marital status was 
married or not married. Age at diagnosis of first breast cancer and number of comorbidities, 
measured based on Medicare inpatient, outpatient, and provider claims data for the year 
preceding the incident breast cancer diagnosis based on the Klabunde algorithm [19] were 
both included as these factors have been shown to influence breast cancer treatment among 
older women [20]. Additional clinical variables included cancer stage, as classified by the 
American Joint Committee on Cancer (AJCC); hormone receptor status classified as 
combined status, estrogen receptor and/or progesterone receptor; and status of node 
examination as positive, negative or no exam.
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Other covariates included diagnosis year, SEER site (San Francisco, Connecticut, Detroit, 
Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose, Los Angeles, Rural Georgia, 
Kentucky, Louisiana, New Jersey, Greater Georgia), and urban status of county of residence 
based on SEER classification, defined as large metropolitan area, metropolitan area, urban or 
rural.
Statistical Analysis
Baseline demographics are described with means and proportions in summary statistics. 
Chi-squared trend tests were used to compare women of differing SES categories according 
to their demographic and clinical characteristics. Logistic regression models were used to 
determine the association between SES and receipt of any axillary surgery, SLNB or ALND, 
post-BCS radiation, neoadjuvant chemotherapy, adjuvant chemotherapy, and type of 
endocrine therapy (AI versus tamoxifen). As clinically indicated, analyses of adjuvant 
chemotherapy were restricted to women with stage II or stage III disease, analyses of post-
BCS radiation were restricted to women undergoing a breast conserving surgery, and 
analyses of hormone therapy were restricted to women with hormone positive disease.
Among those patients who did receive axillary surgery, multinomial logistic regression was 
used to evaluate the probability of receiving either SLNB only, SLNB and ALND, or ALND 
only. In addition to the covariates described above, which were included in all analyses, we 
controlled for node examination status in regressions where neoadjuvant chemotherapy and 
adjuvant chemotherapy were the outcomes of interest in order to control for direction of 
treatment based on extent of disease. Finally, hormone receptor status was included as an 
additional control variable when assessing factors associated with a woman’s likelihood of 
receiving neoadjuvant chemotherapy, adjuvant chemotherapy and radiation. Odds ratios 
(ORs) and 95% confidence intervals (CIs) were calculated. All analyses were performed 
using STATA 12.
Results
Summary characteristics
In total, 11,368 women with incident breast cancer were included in this study, of whom 
34% were poor, 18% were near-poor and 48% were of high socioeconomic status. As shown 
in Table 1, women in our sample were predominantly white and older, reflecting both the 
racial distribution of Medicare beneficiaries and the increased incidence of breast cancer in 
white women. The majority of women lived in metropolitan areas and were unmarried. 
Nearly four out of every five women had hormone receptor positive disease and slightly 
more than half had stage I cancer. Majority of women had nodes examined, but the poor 
cohort were less likely to have had node examination as compared to near-poor and high 
SES women. Among women in the entire sample that did have node examination, majority 
were negative, which correlates to the predominance of stage I cancer. Poor women were 
more likely to have more than one comorbidity whereas high SES women were more likely 
to have no comorbidities.
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Breast Cancer Treatments and Socioeconomic Status
Table 2 shows the distribution of initial and adjuvant breast cancer treatments, overall and by 
socioeconomic status. The majority of women received some type of axillary surgery, with 
SLNB-ALND conversions being the most common axillary procedure performed. Women of 
high SES were more likely to receive strictly SLNB or to have an SLNB attempted while 
poor women were more likely to receive strictly ALND. Among women undergoing a BCS, 
a significant majority received radiation. Only 3% of the sample received neoadjuvant 
chemotherapy with no statistically significant difference in its receipt by SES. The majority 
did not receive adjuvant chemotherapy; among those who did, 36% were near-poor, 34% 
were of high SES and 30% were poor.
One-quarter of women with hormone receptor positive disease who were enrolled in 
Medicare Part D did not receive any form of hormonal therapy. Among the subset of women 
with hormone receptor positive disease, who were enrolled in Medicare Part D and had 
begun hormonal therapy within 12 months from their surgery, the majority received an AI as 
part of their hormonal therapy regimen. This is consistent with the 2005 ASCO guidelines 
that prevailed during the study period.
Table 3 shows the relationship of socioeconomic status and receipt of specific breast cancer 
processes of care, adjusted for the covariates in Table 1. There were significant differences 
in the receipt of breast cancer treatments between poor women and women of high SES. 
Poor women were less likely than high SES women to receive the initial surgical treatments: 
axillary surgery, SLNB, and SLNB-ALND. Additionally, the poor were less likely to receive 
radiation after BCS and adjuvant chemotherapy. No significant differences were observed in 
receipt of neoadjuvant chemotherapy or the use of an AI between poor and high SES 
women.
Near-poor women were less likely than their high SES counterparts to receive an SLNB or 
to have an SLNB-attempted prior to the final ALND. Additionally, near-poor women with 
hormone positive disease were less likely to receive a hormonal therapy regimen that 
included an AI within the first four years of therapy when compared to hormone positive 
disease-women of high SES. There were no significant differences in the receipt of axillary 
surgery, radiation after BCS, neoadjuvant chemotherapy and adjuvant chemotherapy when 
compared to high SES women.
Socioeconomic status also influenced treatment receipt differences between lower SES 
levels, with poor women exhibiting statistically significant differences in treatment when 
compared to their near-poor counterparts (results not shown). All initial surgical treatment 
disparities, except for SLNB, remained even after controls for potential confounders. Poor 
women were less likely than near-poor women to receive axillary surgery (OR 0.69, 95% CI 
0.58–0.82) and SLNB-ALND (OR 0.84, 95% CI 0.72–0.99); they were also less likely to 
receive radiation after BCS (OR 0.69, 95% CI 0.54–0.87). Finally, poor women with stage II 
or III disease were less likely to receive adjuvant chemotherapy (OR 0.79, 95% CI 0.64–
0.97). In contrast, near-poor women were at greater disadvantage in terms of hormonal 
therapy as they were significantly more likely than poor women to rely exclusively on 
tamoxifen than AIs (OR 1.79, 95% CI 1.20–2.66).
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Discussion
In this large, population-based sample of SEER-Medicare beneficiaries, there was a 
significant relationship between SES and receipt of initial surgical and adjuvant treatments 
for incident breast cancer, with poorer populations less likely to receive the same treatments 
as their high SES counterparts. Poor women were less likely than near-poor and high SES 
women to receive almost all treatments studied: axillary surgery, SLNB, post-BCS radiation 
and adjuvant chemotherapy. In addition, near-poor women were less likely than high SES 
women to either receive or have an SLNB attempted. There were no statistically significant 
differences in receipt of neoadjuvant therapy across the three SES groups, perhaps due to the 
low prevalence of neoadjuvant treatment overall during the study period (2006–2009).
An important, new finding concerns receipt of an AI as part of hormonal therapy regimen. 
For the majority of postmenopausal women with hormone receptor-positive disease, there 
are essentially two options for oral endocrine therapy. One is tamoxifen, a drug for which 
efficacy was initially demonstrated in the mid-1980’s. The other choice is to use one of three 
aromatase inhibitor (AI) agents. Based on evidence suggesting that AIs, as initial therapy or 
after 2–3 years of tamoxifen, provided more effective control of breast cancer than 
tamoxifen alone among women with hormone receptor-positive disease, recommendations 
from the American Society of Clinical Oncology, published in 2005 and prevailing during 
the study period, suggested that adjuvant therapy for postmenopausal women with hormone 
receptor-positive breast cancer include an aromatase inhibitor [18,21–23]. Although the AI 
agents have recently become available as generic formulations with a considerably lower 
cost to the patient, for much of the past decade, these agents were significantly more costly 
than tamoxifen. Our results revealed that, for this particular breast cancer treatment, near-
poor women were the most disadvantaged group likely due to their ineligibility for Part D-
specific low-income subsidies despite relative poverty status.
The existing literature on SES disparities in breast cancer treatment often relies on small 
samples drawn from selected populations. A number of U.S. studies have concentrated on 
single state, county or metropolitan analyses to assess SES disparities in use of axillary 
surgery, type of breast surgery, chemotherapy and radiation [24–32]. Current larger 
population-based studies do provide a better idea of the national landscape; however, they 
tend to present piecemeal assessments rarely extending beyond the analysis of one or two 
processes of care, which alone only make up part of a treatment plan. Additionally, this 
study illustrates that disparities are not restricted to comparison between the extremes but 
persist between lower SES cohorts as well.
Several limitations of the study merit comment. Our sample is limited to elderly breast 
cancer beneficiaries enrolled in traditional (Fee-for-Service) Medicare as healthcare 
utilization data are not available for those enrolled in Medicare managed care. As of 2007, 
however, the vast majority (85%) of Medicare beneficiaries were enrolled in such more 
traditional, non-capitated plans [33]. While the median onset of breast cancer in women is 
62 years and women 65 years and older make up more than 40% of breast cancer patients 
[34], our results may not be generalizable to younger patients. Older women have been 
shown to have, on average, better survival than young women. The differences are at least 
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partially attributable to more aggressive tumor grade and molecular subtypes in young 
women, and would imply that elderly women may not as often require as aggressive a 
treatment approach [35]. In addition, our findings of disparities by SES in receipt of 
hormonal therapy are further limited to the subset of women enrolled in the Medicare Part D 
prescription drug program. These findings may not apply to elderly breast cancer patients 
with a different source of coverage, such as private or employer-based pharmaceutical drug 
plans.
Our findings, based on a large sample of elderly Medicare beneficiaries, show substantial 
SES disparities in the receipt of certain breast cancer treatments. In regards to adjuvant 
therapy, our findings are consistent with the emerging literature indicating that women of 
low SES are less likely to receive post-BCS radiation [6,16] and adjuvant chemotherapy 
[6,36] than their wealthier counterparts. Our analyses also uncovered socioeconomic 
disparities in the receipt of other important breast cancer treatments, such as axillary surgery, 
SLNB and hormonal therapy. These results are of particular importance as these processes 
capture the continuum of breast cancer treatment. Axillary surgery, whether it is ALND or 
SLNB, is necessary for adequate biopsy. SLNB, specifically, is imperative to guide quality 
adjuvant treatment for the patient. Our study’s finding of low SES women’s lower likelihood 
of receiving SLNB is consistent with those recently reported by Chen et al and Reeder-
Hayes et al [37,38].
Unlike the medical components (Parts A & B) of Medicare, the U.S. federal health insurance 
program created in 1965 for people ages 65 and over regardless of income, coverage of 
prescription drugs through its Part D program relies on private plans within the various 
states. These plans are allowed wide discretion when setting plan features and prices. Our 
findings regarding near-poor women’s exclusive reliance on tamoxifen for their hormonal 
therapy regimen raises concerns that, while Medicare Part D improved older patients’ access 
to prescription drugs, it did relatively little to reduce socioeconomic variation in use of AIs 
[39–40], the (2005) ASCO-recommended breast cancer oral therapy, for women who were 
not eligible for the program’s low-income subsidy despite relative poverty.
While racial disparities in breast cancer have dominated the literature on the subject and are 
certainly deserving of attention, this study’s focus on socioeconomic disparities has the 
potential to play a vital role in helping eliminate inequalities among larger segments of the 
breast cancer population. Socioeconomic status is often intertwined with race or ethnicity 
and it can be challenging to parse out the effects of each on disparities in healthcare. 
Nonetheless, attention to alleviating socioeconomic disparities, which are more easily 
amenable to policy intervention, can also help reduce lingering disparities by race or 
ethnicity. For example, the highlighted finding of disparity in AI use among the near-poor 
population provides evidence that strategically subsidizing certain socioeconomic 
populations may promote optimal care.
In summary, our results indicate that SES disparities in the receipt of treatments for incident 
breast cancer are both pervasive and substantial. These disparities remained despite controls 
for women’s geographic area of residence and extent of disease. This suggests important 
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disparities-generating gaps in access to effective initial therapy and/or follow-up breast 
cancer care among women of lower socioeconomic status.
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Table 1
Sample Statistics, Overall and by Socioeconomic Statusa
Total Poor Near poor High SES
Total number 11,368 3,869 2,014 5,485
Age, mean (SD) 76 (6) 76(6) 76(6) 75(6)
Race, %
 White 80 63 71 95
 Black 12 19 24 2
 Asian 4 9 1 1
 Hispanic 2 6 1 1
 Native 1 1 1 0
 Other 2 2 2 2
Marital Status, %
 Unmarried 61 80 61 48
 Married 39 20 39 52
Comorbidity, %
 None 48 31 48 61
 1 27 29 28 25
 2+ 25 40 24 14
SEER Stage, %
 I 52 42 50 59
 II 32 37 33 29
 III 11 14 11 8
Hormone Receptor Status, %
 Unknown 6 9 7 4
 Negative 14 16 17 13
 Positive 79 76 76 83
Node status, %
 Negative 60 52 60 66
 Positive 25 29 26 21
 No exam 14 18 13 12
Urban area, %
 Large metro 60 55 37 72
 Metro 28 27 35 26
 Urban 11 15 25 2
 Rural 1 3 3 1
aAll differences were statistically significant at p<0.05 level.
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Table 2
Unadjusted Rate of Breast Cancer Treatments, Overall and by Socioeconomic Status
Total Poor Near poor High SES
Total number 11,368 3,869 2,014 5,485
Axillary Surgery, %
No Axillary Surgery 13 17 12 11
Sentinel Lymph Node Biopsy only (SLNB) 33 26 31 38
Axillary Lymph Node Dissection only (ALND) 17 26 22 9
SLNB-ALND conversion 37 31 35 42
Post breast-conserving surgery radiation1, % 81 75 79 85
Neoadjuvant Chemotherapy, % 3 3 3 3
Adjuvant Chemotherapy2, % 33 30 36 34
Hormonal Therapy, %
Exclusively Tamoxifen3 12 11 20 10
Included an Aromatase Inhibitor3 88 89 80 90
1Among the subset of women who underwent a breast-conserving surgery.
2Among the subset of women with stage II or stage III disease.
3Among the subset of women with hormone receptor positive disease, who were enrolled in Medicare Part D during the study follow-up period and 
who had begun hormonal therapy within 12 months from their surgery.
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Table 3
Odds of Receiving Treatment, Relative to High SES Breast Cancer Patients
Poor
OR (CI)
Near-poor
OR (CI)
Axillary Surgery
Any Axillary Surgery 0.69 (0.59–0.80)** 0.99 (0.83–1.20)
SLNB only 0.71 (0.63–0.80)** 0.78 (0.68–0.89)**
SLNB-ALND conversion 0.38 (0.33–0.45)** † 0.46 (0.38–0.54)** †
Post breast-conserving surgery radiation1 0.59 (0.48–0.72)** 0.85 (0.67–1.08)
Neoadjuvant Chemotherapy 0.83 (0.61–1.10) 1.09 (0.78–1.50)
Adjuvant Chemotherapy2 0.74 (0.61–0.90)** 0.95 (0.76–1.18)
Hormonal Therapy
Exclusively Tamoxifen3 1.20 (0.82–1.76) 2.23 (1.43–3.47)**
*Statistical significance difference at p<0.05;
**Statistical significance difference at p<0.01
†
Results from multinomial logistic regression where the reference category is strictly ALND (i.e., no SLNB attempted).
1Among the subset of women who underwent a breast-conserving surgery.
2Among the subset of women with stage 2 or stage 3 disease.
3Among the subset of women with hormone receptor positive disease, who were enrolled in Medicare Part D during the study follow-up period and 
who had begun hormonal therapy within 12 months from their surgery.
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